Drug intelligence / Profile preview

Herposicc

Development stage: Unknown
Lead developer: Pharmaselect International
Modality: Small Molecules
Administration: Topical

Overview

Herposicc is a topical combination ointment indicated for the symptomatic treatment of herpes labialis (cold sores). It contains benzocaine, which acts as a local anesthetic to alleviate pain and itching, and zinc oxide, which provides astringent and anti-inflammatory properties to support the healing of fever blisters. The product has been available in Austria for over fifty years and is currently marketed by Pharmaselect International as an over-the-counter medication.

Brand names: Herposicc

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on Herposicc.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Herposicc.

Explore the full profile